Phase II study of cisplatin plus epirubicin salvage chemotherapy in refractory germ cell tumors

Pablo M. Bedano, Mary J. Brames, Stephen D. Williams, Beth E. Juliar, Lawrence H. Einhorn

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Purpose: Initial cisplatin (CIS) combination chemotherapy will cure 70% of patients with disseminated testicular cancer. This phase II clinical trial evaluated the combination of CIS plus epirubicin (CIS-EPI) in patients with metastatic germ cell tumors (GCT) not amenable to cure with standard salvage therapy. Patients and Methods: Between March 2001 and August 2005, 30 patients with GCT, who had received at least one previous CIS-based regimen, were enrolled. All patients were males, with median age 36 (range, 24 to 45 years). Twenty-one patients (70%) had experienced late relapses (> 2 years). Patients received EPI 90 mg/m2 on day 1 and CIS 20 mg/m2 on days 1 to 5 every 3 weeks for maximum of four cycles. Results: Nineteen (63%) of 30 patients received all four cycles. Toxicity was primarily hematologic: grade 3/4 neutropenia, four patients (one neutropenic fever); two patients had grade 3 thrombocytopenia, and five patients had grade 3/4 anemia. Nonhematologic toxicity was grade 3 acute renal failure in two patients; grade 3 electrolyte wasting in two patients; grade 3 nausea/vomiting in eight patients; grade 3 elevation of aminotransferases in one patient; and grade 3 diarrhea in one patient. There were no occurrences of severe mucositis, cardiotoxicity, or treatment-related deaths. Nine patients achieved a complete remission; seven of these patients remain without evidence of disease at 25+ , 27+ , 29+, 44+, 45+, 46+, and 48+ months. One patient remains alive with stable pulmonary nodules at 28+ months. Conclusion: CIS-EPI is an active regimen in metastatic GCT, with an acceptable toxicity profile. This regimen offers potential for long-term disease-free survival in this population.

Original languageEnglish (US)
Pages (from-to)5403-5407
Number of pages5
JournalJournal of Clinical Oncology
Volume24
Issue number34
DOIs
StatePublished - Dec 1 2006

Fingerprint

Epirubicin
Germ Cell and Embryonal Neoplasms
Cisplatin
Drug Therapy
Salvage Therapy
Phase II Clinical Trials
Mucositis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Phase II study of cisplatin plus epirubicin salvage chemotherapy in refractory germ cell tumors. / Bedano, Pablo M.; Brames, Mary J.; Williams, Stephen D.; Juliar, Beth E.; Einhorn, Lawrence H.

In: Journal of Clinical Oncology, Vol. 24, No. 34, 01.12.2006, p. 5403-5407.

Research output: Contribution to journalArticle

Bedano, Pablo M. ; Brames, Mary J. ; Williams, Stephen D. ; Juliar, Beth E. ; Einhorn, Lawrence H. / Phase II study of cisplatin plus epirubicin salvage chemotherapy in refractory germ cell tumors. In: Journal of Clinical Oncology. 2006 ; Vol. 24, No. 34. pp. 5403-5407.
@article{73af74fefb324d468b5a25d47e9f91d2,
title = "Phase II study of cisplatin plus epirubicin salvage chemotherapy in refractory germ cell tumors",
abstract = "Purpose: Initial cisplatin (CIS) combination chemotherapy will cure 70{\%} of patients with disseminated testicular cancer. This phase II clinical trial evaluated the combination of CIS plus epirubicin (CIS-EPI) in patients with metastatic germ cell tumors (GCT) not amenable to cure with standard salvage therapy. Patients and Methods: Between March 2001 and August 2005, 30 patients with GCT, who had received at least one previous CIS-based regimen, were enrolled. All patients were males, with median age 36 (range, 24 to 45 years). Twenty-one patients (70{\%}) had experienced late relapses (> 2 years). Patients received EPI 90 mg/m2 on day 1 and CIS 20 mg/m2 on days 1 to 5 every 3 weeks for maximum of four cycles. Results: Nineteen (63{\%}) of 30 patients received all four cycles. Toxicity was primarily hematologic: grade 3/4 neutropenia, four patients (one neutropenic fever); two patients had grade 3 thrombocytopenia, and five patients had grade 3/4 anemia. Nonhematologic toxicity was grade 3 acute renal failure in two patients; grade 3 electrolyte wasting in two patients; grade 3 nausea/vomiting in eight patients; grade 3 elevation of aminotransferases in one patient; and grade 3 diarrhea in one patient. There were no occurrences of severe mucositis, cardiotoxicity, or treatment-related deaths. Nine patients achieved a complete remission; seven of these patients remain without evidence of disease at 25+ , 27+ , 29+, 44+, 45+, 46+, and 48+ months. One patient remains alive with stable pulmonary nodules at 28+ months. Conclusion: CIS-EPI is an active regimen in metastatic GCT, with an acceptable toxicity profile. This regimen offers potential for long-term disease-free survival in this population.",
author = "Bedano, {Pablo M.} and Brames, {Mary J.} and Williams, {Stephen D.} and Juliar, {Beth E.} and Einhorn, {Lawrence H.}",
year = "2006",
month = "12",
day = "1",
doi = "10.1200/JCO.2006.05.8065",
language = "English (US)",
volume = "24",
pages = "5403--5407",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "34",

}

TY - JOUR

T1 - Phase II study of cisplatin plus epirubicin salvage chemotherapy in refractory germ cell tumors

AU - Bedano, Pablo M.

AU - Brames, Mary J.

AU - Williams, Stephen D.

AU - Juliar, Beth E.

AU - Einhorn, Lawrence H.

PY - 2006/12/1

Y1 - 2006/12/1

N2 - Purpose: Initial cisplatin (CIS) combination chemotherapy will cure 70% of patients with disseminated testicular cancer. This phase II clinical trial evaluated the combination of CIS plus epirubicin (CIS-EPI) in patients with metastatic germ cell tumors (GCT) not amenable to cure with standard salvage therapy. Patients and Methods: Between March 2001 and August 2005, 30 patients with GCT, who had received at least one previous CIS-based regimen, were enrolled. All patients were males, with median age 36 (range, 24 to 45 years). Twenty-one patients (70%) had experienced late relapses (> 2 years). Patients received EPI 90 mg/m2 on day 1 and CIS 20 mg/m2 on days 1 to 5 every 3 weeks for maximum of four cycles. Results: Nineteen (63%) of 30 patients received all four cycles. Toxicity was primarily hematologic: grade 3/4 neutropenia, four patients (one neutropenic fever); two patients had grade 3 thrombocytopenia, and five patients had grade 3/4 anemia. Nonhematologic toxicity was grade 3 acute renal failure in two patients; grade 3 electrolyte wasting in two patients; grade 3 nausea/vomiting in eight patients; grade 3 elevation of aminotransferases in one patient; and grade 3 diarrhea in one patient. There were no occurrences of severe mucositis, cardiotoxicity, or treatment-related deaths. Nine patients achieved a complete remission; seven of these patients remain without evidence of disease at 25+ , 27+ , 29+, 44+, 45+, 46+, and 48+ months. One patient remains alive with stable pulmonary nodules at 28+ months. Conclusion: CIS-EPI is an active regimen in metastatic GCT, with an acceptable toxicity profile. This regimen offers potential for long-term disease-free survival in this population.

AB - Purpose: Initial cisplatin (CIS) combination chemotherapy will cure 70% of patients with disseminated testicular cancer. This phase II clinical trial evaluated the combination of CIS plus epirubicin (CIS-EPI) in patients with metastatic germ cell tumors (GCT) not amenable to cure with standard salvage therapy. Patients and Methods: Between March 2001 and August 2005, 30 patients with GCT, who had received at least one previous CIS-based regimen, were enrolled. All patients were males, with median age 36 (range, 24 to 45 years). Twenty-one patients (70%) had experienced late relapses (> 2 years). Patients received EPI 90 mg/m2 on day 1 and CIS 20 mg/m2 on days 1 to 5 every 3 weeks for maximum of four cycles. Results: Nineteen (63%) of 30 patients received all four cycles. Toxicity was primarily hematologic: grade 3/4 neutropenia, four patients (one neutropenic fever); two patients had grade 3 thrombocytopenia, and five patients had grade 3/4 anemia. Nonhematologic toxicity was grade 3 acute renal failure in two patients; grade 3 electrolyte wasting in two patients; grade 3 nausea/vomiting in eight patients; grade 3 elevation of aminotransferases in one patient; and grade 3 diarrhea in one patient. There were no occurrences of severe mucositis, cardiotoxicity, or treatment-related deaths. Nine patients achieved a complete remission; seven of these patients remain without evidence of disease at 25+ , 27+ , 29+, 44+, 45+, 46+, and 48+ months. One patient remains alive with stable pulmonary nodules at 28+ months. Conclusion: CIS-EPI is an active regimen in metastatic GCT, with an acceptable toxicity profile. This regimen offers potential for long-term disease-free survival in this population.

UR - http://www.scopus.com/inward/record.url?scp=34247161758&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247161758&partnerID=8YFLogxK

U2 - 10.1200/JCO.2006.05.8065

DO - 10.1200/JCO.2006.05.8065

M3 - Article

C2 - 17135640

AN - SCOPUS:34247161758

VL - 24

SP - 5403

EP - 5407

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 34

ER -